mepolizumab | Ricerc@Sapienza

VEGF/VEGFRs nasal expression is reduced by Mepolizumab in chronic rhinosinusitis with nasal polyposis

Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a phenotype of chronic rhinosinusitis characterized by the presence of nasal polyps. To date, medical therapy and surgery can manage the disease in most of the cases. However, despite improvements in surgical techniques, CRSwNP is characterized by relapses in severe cases, thus leading to the study of biological drugs such as Mepolizumab, antagonizing IL-5.

The spectrum of therapeutic activity of mepolizumab

Introduction: The basis of the development of the anti-interleukin-5 monoclonal antibody mepolizumab was the acknowledgment of the crucial importance of this cytokine in promoting eosinophils

Recovery of smell sense loss by mepolizumab in a patient allergic to dermatophagoides and affected by chronic rhinosinusitis with nasal polyps

Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) frequently presents with dysfunction or loss of the
sense of smell, resulting in a signifcant impairment in quality of life. The medical treatments currently available may
improve the olfactory function in patients with CRSwNP, but such an outcome is generally only transitory. We report
the case of a patient with CRSwNP who completely recovered from smell sense loss by treatment with mepolizumab.

Mepolizumab effectiveness and allergic status in real life

Background: It is not clear whether mepolizumab is differently effective in allergic and nonallergic severe eosinophilic asthmatics (SEA) in real life. Objective: We tested mepolizumab effectiveness in allergic/nonallergic SEA in real life. A strict criterion to identify the 2 phenotypes was used.

Real-life Mepolizumab effectiveness in severe eosinophilic asthmatics with nasal polyposis

Nasal polyposis (NP) is a chronic paranasal sinuses inflamma-tory disease causing severe nasal and systemic symptoms includingfatigue, sleeping problems, and impairments in social, emotionaland lifestyle conditions. Patients with severe eosinophilic asthma (SEA) have frequent comorbid NP, which may impact asthma severity.

Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life

BACKGROUND:
Mepolizumab (MEP) has been recently introduced to treat severe eosinophilic asthma. Trials have demonstrated a significant effectiveness in this asthma phenotype. We evaluated MEP efficacy on lung function, symptoms, asthma exacerbations, biologic markers, steroid dependence and controller treatment level in real-life.
METHODS:
We retrospectively analyzed 134 severe asthmatics (61 males; mean age 58.3 ± 11; mean FEV1%:72 ± 21), treated with MEP for at least 6 months (mean duration:10.9 ± 3.7 months).
RESULTS: